Published Research
About Our Custom Vaccines
Custom Made Vaccines have been used for many years to help address livestock diseases. Newport Laboratories has applied 21st century technology to the traditional autogenous approach to produce high quality biologics for the livestock industry. These products are formulated and produced to pinpoint the specific disease problems in your livestock. Our dedicated employees, quality products, innovative solutions and personalized customer service, are the catalyst for Newport Laboratories’ success. Today, we provide Custom Made Vaccines for customers across the country.
We invite you to look through this section of our website, and contact us to discuss how Newport Laboratories can become your partner in improving and maintaining the health of your livestock. Custom Made Vaccines are sold exclusively through practicing veterinarians. For more information about Custom Made Vaccines, contact Newport Laboratories at 800-220-2522 or contact us.
-
Ben M. Hause,1 Tracy A. Oleson, Russell F. Bey,
Douglas L. Stine, Randy R. SimonsonAbstract
In vivo, neutralizing antibodies are critical for viral clearance. A high-throughput serum neutralization (HTSN) assay was developed to antigenically categorize Swine influenza virus (SIV) isolates. Uncategorized viruses were tested using a panel of antisera representing the H3N2 SIV subtypes and the results expressed as a serum neutralization ratio. Antisera were generated against contemporary isolates representing circulating H3N2 SIV subtypes (clusters I, III, IV). Reference viruses and the corresponding antisera were evaluated using traditional hemagglutination inhibition (HI) and the HTSN assays and good correlation (r 5 0.84) was observed between the 2 tests. Categorical clustering of 40 recent (2008–2009) SIV isolates was assessed using the HTSN assay. The H3N2 SIV isolates with amino acid similarity. 97% to the commonly used H3N2 cluster IV reference strain A/Swine/Ontario/33853/2005 (ON05) showed strong reactivity with cluster IV antisera. Isolates with, 97% amino acid similarity to ON05 sporadically or completely failed to react with any antiserum. A cluster of 3 isolates with weak reaction with cluster III antiserum may be a potential emerging cluster of H3N2 with moderate genetic similarity to cluster II H3N2 (93% similarity). Potential uses of the HTSN assay include identification of broadly cross-reactive or antigenically distinct SIV isolates for use in vaccine virus selection or as part of surveillance efforts monitoring antigenic drift.
Download Article: Click here
-
Genetic and antigenic characterization of recent human-like H1 (d-cluster) Swine Influenza Virus isolates
Ben M. Hause, MS; Tracy A. Oleson, MS; Douglas L. Stine, DVM, PhD; Russell F. Bey, PhD; Randy R. Simonson, PhDTo assess genetic and antigenic properties of contemporary human-like H1 (d-cluster) swine influenza virus (SIV) isolates circulating in US swine herds. (As published in the Journal of Swine Health & Production)
Download Article: Click here
-
Mariette F. Ducatez, Ben Hause, Evelyn Stigger-Rosser, Daniel Darnell, Cesar Corzo, Kevin Juleen, Randy Simonson, Christy Brockwell-Staats, Adam Rubrum, David Wang, Ashley Webb, Jeri-Carol Crumpton, James Lowe, Marie Gramer, and Richard J. Webby
As a result of human-to-pig transmission, pandemic influenza A (H1N1) 2009 virus was detected in pigs soon after it emerged in humans. In the United States, this transmission was quickly followed by multiple reassortment between the pandemic virus and endemic swine viruses. Nine reassortant viruses representing 7 genotypes were detected in commercial pig farms in the United States. Field observations suggested that the newly described reassortant viruses did not differ substantially from pandemic (H1N1) 2009 or endemic strains in their ability to cause disease. Comparable growth properties of reassortant and endemic viruses in vitro supported these observations; similarly, a representative reassortant virus replicated in ferrets to the same extent as did pandemic (H1N1) 2009 and endemic swine virus. These novel reassortant viruses highlight the increasing complexity of influenza viruses within pig populations and the frequency at which viral diversification occurs in this ecologically important viral reservoir.
Download Article: Click here
-
Abby R. Patterson, John K. Johnson, Sheela Ramamoorthy, Richard A. Hesse,
Michael P. Murtaugh, Sumathy Puvanendiran, Roman M. Pogranichniy, Gene A. Erickson,
Susy Carman, Ben Hause, Xiang-Jin Meng, TanjaOpriessnigAbstract
A blinded interlaboratory assessment of the diagnostic agreement and accuracy of serologic tests for routine detection of antibodies against Porcine circovirus-2 (PCV-2), including indirect fluorescent antibody tests (IFATs) and enzyme-linked immunosorbent assays (ELISAs) was conducted in 7 North American laboratories. Serum samples were collected weekly, on trial days 0, 7, 14, 21, 28, 35, 42, and 49, from the following groups of animals: 1) negative controls ( n 5 7), 2) PCV-2a ( n 5 8), 3) PCV-2b ( n 5 8), 4) PCV-1 ( n 5 8), 5) PCV-2 vaccine A ( n 5 8; Ingelvac H CircoFLEX TM ), 6) PCV-2 vaccine B ( n 5 8; Circumvent H PCV2), and 7) PCV-2 vaccine C ( n 5 8; Suvaxyn H PCV2 One Dose). Results from each laboratory were analyzed by kappa and receiver operating characteristic (ROC) analysis.
Kappa analysis indicated that, by trial day 49, IFATs had almost perfect agreement, in-house ELISAs had fair to almost perfect agreement, and commercially available anti–PCV-2 immunoglobulin G ELISAs (I or S) had moderate to substantial agreement. From trial days 14–49, the area under the ROC curve for the 2 laboratories that offered IFATs, the 4 laboratories that offered in-house ELISAs, and the 3 laboratories that used commercially available ELISAs ranged from 0.94 to 1.00, 0.72 to 1.00, and 0.95 to 1.00, respectively. However, test sensitivities varied based on laboratory-specific cutoffs that were used to dichotomize test results.